Editor-in-Chief Hatice Kübra Elçioğlu Vice Editors Levent Kabasakal Esra Tatar Online ISSN 2630-6344 Publisher Marmara University Frequency Bimonthly (Six issues / year) Abbreviation J.Res.Pharm. Former Name Marmara Pharmaceutical Journal
Marmara Pharmaceutical Journal 1995 , Vol 11 , Issue 1 - 2
Preclinical antitumor activity of a novel olivacine derivative: S 16020-2 (NCS-659687)
G. Atassi,A. Pierre,N.Guilbaud,L.Kraus-Berthier,D. Saint-Dizier,E.Bisagni
Structural modifications to develop olivacine analogs with reduced cross-resistance and side effects resulted in the discovery of S 16020-2. This drug showed a very potent cytotoxic effet in vitro and high therapeutic antitumor activity in vivo. 60% of P388-bearing mice were cured following the administration of 60 mg/kg/day (with an intermittent schedule) x3. The drug was still significantly active against the resistant P388/VCR model while adriamycin was totally inactive. Three intermittent injections of 40 mg/kg induced 100% cure in established Lewis lung carcinoma. Xenografts of human H-69 small cell lung carcinoma and H460 non small cell lung carcinoma were significantly sensitive to S 16020-2. These properties deserve further pharmacotoxicological studies. Keywords :
Marmara University